Advanced search
Start date
Betweenand

Association of SPOP, CHD1 and PTEN expression with recurrence in high-risk prostate cancer patients

Grant number: 22/13507-5
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Effective date (Start): May 01, 2023
Effective date (End): December 31, 2023
Field of knowledge:Health Sciences - Medicine - Surgery
Principal Investigator:Sabrina Thalita dos Reis Faria
Grantee:Giovana Vilas Boas Caetano
Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Prostate cancer (PCa) is a public health issue and is considered the second most frequent type of tumor in the male population worldwide. According to INCA, in 2020, the PCa was responsible for 358,301 deaths. Screening is done preventively through PSA measurement, and diagnosis is made by biopsy. The prognosis is based on PSA dosage, pathological stage, tumor volume, and histological grade; the last one is the most important. PCa has complex genetics, and many genes and molecular alterations have already been associated with its carcinogenesis and progression. It has already been demonstrated that primary PCa has mutations in tumor suppressors, such as the SPOP, CDH1, and PTEN genes. SPOP gene promotes the degradation of oncoproteins that regulate cellular processes such as cell cycle and metabolism, invasion, and apoptosis and controls the stability of the androgen receptor (AR) protein damage related to this gene can be intensified with the deletion of CDH1, which is an adhesion and anchoring gene and is also involved in the transmission of chemical signals within cells when mutated leads to a worse prognosis. Finally, the loss of PTEN gene is associated with a worse prognosis, and its absence modifies numerous pathways that can accelerate the development of the disease. Therefore, as it is a disease with heterogeneity, it is essential to study the genes that may be associated with tumor progression, being essential for understanding the molecular basis. With this, this project proposes to evaluate the expression of CDH1, SPOP, and PTEN genes in the PCa of high risk, next to correlating the expression levels with the clinical pathological data of the patients, analyzing which patients will or will not progress to disease recurrence and biochemistry. In addition, analyzing the mutations of such games with the help of bioinformatics through databases. For this, we selected 60 patients diagnosed with PCa, who underwent surgical treatment for the disease and a control group, samples from 5 patients with benign prostatic hyperplasia (BPH) will be used. To analyze the expression levels of the genes, we will extract the total RNA from the samples using conventional extraction methods; then, we will perform the qPCR analysis using specifically for each selected gene.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Please report errors in scientific publications list using this form.